基线因素对糖尿病黄斑水肿患者玻璃体内注射阿柏西普或激光治疗后糖尿病视网膜病变严重程度量表评分变化的影响:VISTA 与 VIVID 事后分析
基于 VISTA 和 VIVID 两项 3 期试验的事后分析,纳入 456 例中心受累糖尿病黄斑水肿患者,评估基线全身及眼部因素对第 100 周 DRSS 评分≥2 级改善的影响。结果显示,仅基线 DRSS 评分在所有治疗组中与≥2 级改善显著相关,年龄、糖尿病病程、HbA1c、BMI、BCVA、CST 均无影响。
要点
- 第 100 周时,激光组、2q4 组、2q8 组分别有 10.1%、34.3%、37.6% 患者实现 DRSS 评分≥2 级改善。
- 基线 DRSS 评分是唯一在所有治疗组第 24、52、76、100 周均与≥2 级改善显著相关的因素。
- 年龄、糖尿病病程、HbA1c、BMI、BCVA、CST 对实现 DRSS 评分≥2 级改善无影响。
核心结论
- 在 VISTA 和 VIVID 的糖尿病黄斑水肿患者中,基线 DRSS 评分与第 100 周 DRSS 评分≥2 级改善存在强关联。
研究设计与样本
- VISTA 和 VIVID 两项设计相似的 3 期试验的事后分析,共纳入 456 例中心受累糖尿病黄斑水肿患者,按各特征三分位分组进行逻辑回归分析。
主要发现
- 第 100 周时,激光组、2q4 组、2q8 组分别有 10.1%、34.3%、37.6% 患者实现 DRSS 评分≥2 级改善。
- 年龄、糖尿病病程、HbA1c、BMI、BCVA、CST 对实现 DRSS 评分≥2 级改善无影响。
- 基线 DRSS 评分是唯一在所有治疗组第 24、52、76、100 周均与≥2 级 DRSS 评分改善显著相关的因素。
- BCVA 较差或 CST 较厚的 IAI 治疗患者实现≥2 级 DRSS 评分改善的比例相对较高,但这些关联未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether select baseline systemic and ocular factors influence ≥2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) score at week 100 in VISTA and VIVID. DESIGN: Post hoc analysis of 2 similarly designed phase 3 trials, VISTA and VIVID. PARTICIPANTS: Total of 456 patients with center-involved diabetic macular edema (DME). METHODS: VISTA and VIVID randomized 872 DME patients to receive intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular laser photocoagulation. This post hoc analysis evaluated the influence of select baseline factors on ≥2-step DRSS score improvement by logistic regression in an integrated VISTA and VIVID dataset using observed cases (n = 456) with patients in each treatment group divided into tertiles based on each characteristic. MAIN OUTCOME MEASURES: Proportion of patients with ≥2-step improvement in DRSS score from baseline at week 100 by age, duration of diabetes, hemoglobin A1c (HbA1c), body mass index (BMI), best-corrected visual acuity (BCVA), central subfield thickness (CST), and DRSS score. RESULTS: At week 100, 10.1%, 34.3%, and 37.6% of patients in the laser, 2q4, and 2q8 groups experienced a ≥2-step DRSS score improvement, respectively. Age, duration of diabetes, HbA1c, BMI, BCVA, and CST had no impact on the ability to achieve ≥2-step improvement in DRSS score. Initial DRSS score was the only factor significantly associated with ≥2-step DRSS score improvement in all treatment groups at weeks 24, 52, 76, and 100. Relatively higher proportions of IAI-treated patients with worse BCVA or thicker CST experienced ≥2-step DRSS score improvement compared with those with better BCVA or thinner CST, respectively, but these associations were not statistically significant. CONCLUSION: A strong association was present between baseline DRSS score and ≥2-step DRSS score improvement at week 100 for DME patients in VISTA and VIVID.
引用
- Dhoot DS, Baker K, Saroj N, et al. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID. Ophthalmology. 2017. PMID: 28764888. doi:10.1016/j.ophtha.2017.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。